BYL719 reverses gefitinib-resistance induced by PI3K/AKT activation in non-small cell lung cancer cells

Non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutation often obtain de novo resistance or develop secondary resistance to EGFR tyrosine kinase inhibitors (EGFR-TKIs), which restricts the clinical benefit for the patients. The activation of phosphatidylinosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Yaya, Xiao, Zhenzhen, Lei, Chenjing, Ma, Changju, Ding, Lina, Tang, Qing, He, Yihan, Chen, Yadong, Chang, Xuesong, Zhu, Yanjuan, Zhang, Haibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408073/
https://www.ncbi.nlm.nih.gov/pubmed/37553597
http://dx.doi.org/10.1186/s12885-023-11243-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10408073/
https://www.ncbi.nlm.nih.gov/pubmed/37553597
http://dx.doi.org/10.1186/s12885-023-11243-0

Ejemplares similares